296 results about "Biphenyl compound" patented technology

This invention provides compounds of formula I:wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

The invention belongs to the field of agricultural acaricides, and concretely relates to a biphenyl compound and an application thereof. The structure of the compound is represented by general formula I, and all substituent groups in the general formula I are defined in the description. The compound of the general formula I has excellent acaricidal activity, and can be used to prevent and control various mite damages.

This invention provides compounds of formula I:wherein a, b, c, d, m, n, p, r, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

This invention provides compounds of formula I:wherein a, b, c, m, p, r, R1, R2, R3, R4, R5, R6, W and X1 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

In order to manufacture a lithium secondary battery having excellent performances in safety under overcharge condition, cycle property, electric capacity, and storage endurance, 0.1 wt. % to 10 wt. % of a tert-alkylbenzene compound is favorably incorporated into a non-aqueous electrolytic solution comprising a non-aqueous solvent and an electrolyte, preferably in combination with 0.1 wt. % to 1.5 wt. % of a biphenyl compound.

A process for the preparation of a biphenyl-containing compound of general formula I: wherein R1 is a C3-6 carbonyl containing compound; R2 is a substituted or unsubstituted, straight or branched C3-6 alkyl group, or R1 and R2 together with the nitrogen atom to which they are bonded are joined together to form a substituted heterocyclic group selected from the group consisting of substituted or unsubstituted imidazoles, substituted or unsubstituted benzimidazoles and substituted or unsubstituted 1,3-diazaspiro[4,4]non-1-en-4-one; and R3 is a carboxylic acid ester, cyano, a substituted or unsubstituted 1H-tetrazolyl group or a substituted or unsubstituted group which may be converted in vivo into a carboxy group is provided, the process comprising reacting a compound of general formula II: wherein R1 and R2 have the aforestated meanings with a compound of general formula III: wherein Z is a leaving group and R3 has the aforestated meaning in a biphasic solvent system in the presence of a phase transfer catalyst.

This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, r, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

This invention provides compounds of formula I:wherein a, b, c, d, m, n, p, r, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

This invention provides compounds of formula I:wherein a, b, c, d, m, n, p, s, t, Ar1, R1, R2, R3, R4, R6, R7, R8, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

The present invention discloses bisphenyl compounds of the formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W are defined herein after. These compounds are useful as pharmaceuticals.

This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

The problem that the invention object to resolve is to provide a polymerizable compound, which has excellent solubility with other liquid crystal compounds during constituting a polymerizable liquid crystal composition, and displays excellent heat-resistant quality and mechanical intensity during curing the polymerizable liquid crystal composition. The invention provides a polymerizable compound represented by formula (I), and a liquid crystal composition taking the compound as the constitution material, and further provides an optical anisotropy body or liquid crystal device using the liquid crystal composition. As the inventive polymerizable compound has excellent solubility with other liquid crystal compounds, it is useful as the constitution material of the polymerizable compound. In addition, the polymerizable composition containing the inventive polymerizable compound has wide liquid crystal phase temperature range; the optical anisotropy body of the polymerism composition has high heat-resistant quality, and is useful in phase difference plates and the like applications.

The invention is directed to certain biphenyl compounds. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and Y are as defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are KSP inhibitors, particularly human KSP inhibitors, and can be useful for the treatment for a variety of diseases and conditions, such as cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders, fungal disorders, and inflammation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting KSP and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. In an additional aspect, the invention provides methods of screening for compounds that will bind to a KSP kinesin, for example compounds that will displace or compete with the binding of the compounds of the invention. The methods comprise combining a labeled compound of the invention, a KSP kinesin, and at least one candidate agent and determining the binding of the candidate bioactive agent to the KSP kinesin. In a further aspect, the invention provides methods of screening for modulators of KSP kinesin activity. The methods comprise combining a compound of the invention, a KSP kinesin, and at least one candidate agent and determining the effect of the candidate bioactive agent on the KSP kinesin activity.

The invention relates to a green synthesis method of a bromomethylbiphenyl compound, comprising the following steps: dissolving a 4'-methyl-2-substituted biphenyl compound in an organic solvent, adding a bromizating agent to carry out bromination reaction and controlling the reaction conditions to obtain the bromomethylbiphenyl compound. The invention is characterized in that the reaction is carried out in light.

The invention provides a terphenyl bridged double-benzimidazoles compound as well as a synthesis method and application thereof. The invention takes cyanophoric phenyloboricacid and aromatic dibromide (such as 1,4-dibromo-benzene, 2-fluorine-1, 4-dibromo-benzene, 2,5-dibromo-toluene) as raw materials; under the catalysis of organic palladium and inorganic base, a series of terphenyl compounds with di-cyan can be synthesized by the Suzuki coupling reaction; and then a series of terphenyl bridged double-benzimidazoles compounds can be obtained by adding 1 time of di-cyano-terphenyl compounds and 2-2.4 times of o-phenylenediamine compounds, taking polyphosphoric acid as the catalyst and carrying out the condensation reaction for 6-24 hours under 180-240 degrees C.. The compound can be applied to the fields such as light emitting devices, photovoltaic cells, organic light-emitting diodes and the like as the organic blue-light material or the electron transport material.

The invention relates to a synthetic method of biphenyl compounds. Based on novel coupling reaction of phenylhydrazine or benzenesulfonyl hydrazide, the phenylhydrazine or benzenesulfonyl hydrazide is used as a substrate, and coupled after being acted by transition metal in a catalytic manner, so that the biphenyl compounds can be conveniently and effectively combined. Compared with the existing method, the synthetic method disclosed by the invention is extensive in applicable substrate range, mild in reaction condition, simple and convenient to operate and high in reaction efficiency, and is a method with important application value. The method disclosed by the invention is further used for synthesizing biphenyl compounds containing halogens. The invention provides a simple, novel and efficient method.